# EDGAR Filing Document

**Accession Number:** 0001899123
**File Stem:** 0001213900-26-018174
**Filing Date:** 2026-2
**Character Count:** 7591
**Document Hash:** fb1634275e821db76f32f06209a56b61
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-018174.hdr.sgml**: 20260219

**ACCESSION NUMBER**: 0001213900-26-018174

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260219

**DATE AS OF CHANGE**: 20260219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bitdeer Technologies Group
- **CENTRAL INDEX KEY:** 0001899123
- **STANDARD INDUSTRIAL CLASSIFICATION:** FINANCE SERVICES [6199]
- **ORGANIZATION NAME:** 09 Crypto Assets
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-283732
- **FILM NUMBER:** 26651640

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 08 KALLANG AVENUE, APERIA TOWER 1, #09-0
- **CITY:** SINGAPORE
- **PROVINCE COUNTRY:** U0
- **BUSINESS PHONE:** 65-62828220

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 08 KALLANG AVENUE, APERIA TOWER 1, #09-0
- **CITY:** SINGAPORE
- **PROVINCE COUNTRY:** U0

**Filed Pursuant to Rule 424(b)(5)**

**Registration No. 333-283732**

**Amendment No. 2, dated February 19, 2026**

(To Prospectus Supplement dated January 3, 2025

and Prospectus dated December 18, 2024)

**Up to US$700,000,000**

![](image_001.jpg)

**Bitdeer Technologies Group**

**Class A Ordinary Shares**

This prospectus supplement amendment No. 2 (this "amendment No. 2") amends the prospectus supplement, dated January 3, 2025, filed pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended (File No. 333-283732) (the "prospectus supplement"), as amended by the prospectus supplement amendment No. 1, dated November 12, 2025 ("amendment No. 1"). This amendment No. 2 should be read in conjunction with the prospectus supplement, as amended by amendment No. 1, and the accompanying prospectus, dated December 18, 2024 (the "prospectus"), and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the prospectus supplement, as amended by amendment No. 1, and the prospectus. This amendment No. 2 is not complete without, and may only be delivered or utilized in connection with, the prospectus supplement, as amended by amendment No. 1, and the prospectus and any future amendments or supplements thereto.

On January 3, 2025, we entered into an At Market Issuance Sales Agreement (the "sales agreement") with Barclays Capital Inc. ("Barclays"), Cantor Fitzgerald & Co. ("Cantor"), A.G.P./Alliance Global Partners ("AGP"), The Benchmark Company, LLC ("Benchmark"), B. Riley Securities, Inc. ("B. Riley Securities"), BTIG, LLC ("BTIG"), Keefe, Bruyette & Woods, Inc. ("KBW"), Needham & Company, LLC ("Needham"), Northland Securities, Inc. ("Northland"), Rosenblatt Securities Inc. ("Rosenblatt"), Roth Capital Partners, LLC ("Roth") and StockBlock Securities LLC ("StockBlock," and each of Barclays, Cantor, AGP, Benchmark, B. Riley Securities, BTIG, KBW, Needham, Northland, Rosenblatt, Roth and StockBlock, a "Sales Agent" and collectively, the "Sales Agents"), relating to the sale of our Class A ordinary shares, with a par value of US$0.0000001 each (the "Class A ordinary shares"), offered by the prospectus supplement and the accompanying prospectus.

The prospectus supplement was amended by amendment No. 1, solely to reflect a reduction in the total aggregate offering price of Class A ordinary shares we may offer and sell under the prospectus supplement and the accompanying prospectus from US$1,000,000,000 to US$750,000,000.

We are filing this amendment No. 2 to amend the prospectus supplement solely to reflect a further reduction in the total aggregate offering price of Class A ordinary shares we may offer and sell under the prospectus supplement and the accompanying prospectus from US$750,000,000 to US$700,000,000. In accordance with the terms of the sales agreement, under the prospectus supplement, as amended by amendment No. 1 and this amendment No. 2, we may offer and sell our Class A ordinary shares having an aggregate offering price of up to US$700,000,000 from time to time through or to the sales agents, as agent or principal. As of the date of this amendment, we have sold Class A ordinary shares pursuant to the sales agreement for aggregate gross proceeds of US$130.4 million, which are included in the US$700,000,000 of our Class A ordinary shares we may offer and sell under the prospectus supplement and the accompanying prospectus.

Sales of our Class A ordinary shares, if any, under the prospectus supplement, as amended by amendment No. 1 and this amendment No. 2, and the accompanying prospectus, may be made in negotiated transactions, including block trades, or transactions that are deemed to be "at the market" offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"), including sales made by means of ordinary brokers' transactions, including directly on The Nasdaq Capital Market ("Nasdaq") or sales made to or through a market maker other than on an exchange at prevailing market prices, at prices related to prevailing market prices or at negotiated prices or by any other method permitted by law. Subject to the terms of the sales agreement, the Sales Agents are not required to sell any specific amount, but will act as our Sales Agents using commercially reasonable efforts consistent with their normal trading and sales practices. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.

The designated Sales Agent will be entitled to compensation at a commission rate of up to 3.0% of the gross sales price of any Class A ordinary shares sold under the sales agreement. In connection with the sale of Class A ordinary shares on our behalf, each Sales Agent will be deemed to be an "underwriter" within the meaning of the Securities Act and the compensation of the Sales Agents will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Sales Agents with respect to certain liabilities, including civil liabilities under the Securities Act. See "Plan of Distribution" beginning on page S-13 of the prospectus supplement for additional information regarding the compensation to be paid to the Sales Agents.

Our Class A ordinary shares are currently listed on Nasdaq under the symbol "BTDR." On February 18, 2026, the last reported sales price of our Class A ordinary shares was US$9.61 per share.

**Investing in our securities involves a high degree of risk. See the "*Risk Factors*" section beginning on page S-8 of the prospectus supplement and any risk factors in our U.S. Securities and Exchange Commission filings that are incorporated by reference in the prospectus supplement.**

**None of the U.S. Securities and Exchange Commission or any state securities commission has approved or disapproved of the securities or determined if the prospectus supplement or the accompanying prospectus is accurate or adequate. Any representation to the contrary is a criminal offense.**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Barclays** | **Barclays** |  | **Cantor** | **Cantor** |
| **A.G.P.** | **The Benchmark Company** | **B. Riley Securities** | **BTIG** | **Keefe, Bruyette & Woods**<br> *A Stifel Company* |
| **Needham & Company** | **Northland Capital Markets** | **Rosenblatt** | **Roth Capital Partners** | **StockBlock** |

---

This Amendment No. 2 to the Prospectus Supplement is dated February 19, 2026